| Dr Ram L Ramani, MD | |
|
901 Mcclintock Dr, Suite 201, Burr Ridge, IL 60527-0872 | |
| (888) 220-6432 | |
| (630) 654-4253 |
| Full Name | Dr Ram L Ramani |
|---|---|
| Gender | Male |
| Speciality | Infectious Disease |
| Experience | 35 Years |
| Location | 901 Mcclintock Dr, Burr Ridge, Illinois |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1982603387 | NPI | - | NPPES |
| 036087800 | Medicaid | IL | |
| 3160176976 | Other | IL | BLUE SHIELD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RI0200X | Internal Medicine - Infectious Disease | 036087800 (Illinois) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Alexian Brothers Medical Center 1 | Elk grove village, IL | Hospital |
| St Alexius Medical Center | Hoffman estates, IL | Hospital |
| Adventist Glenoaks | Glendale heights, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Metro Infectious Disease Consultants Llc | 3072425784 | 297 |
News Archive
Investigators at Montefiore Health System and Albert Einstein College of Medicine of Yeshiva University will present multiple findings at the Alzheimer's Association International Conference, taking place July 18-23 in Washington, D.C. Research topics include risk factors for developing amnestic mild cognitive impairment (aMCI)—a condition characterized by memory problems, and is most often a precursor of Alzheimer's dementia.
Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, today announced that 12-month data from its Phase 2 CUPID clinical trial of MYDICAR demonstrated significant improvements in clinical outcomes and key disease markers in advanced heart failure patients treated with the genetically-targeted enzyme replacement therapy.
Even though there is considerable opinion among Israelis that much of the public social programs and projects should be the responsibility of the government, the public nevertheless views philanthropic activity in a highly positive light and believes that it plays an essential role in Israeli society.
With a $4.6 million grant from the National Institutes of Health (under the Bioengineering Research Partnership program), research led by Rensselaer Polytechnic Institute will make its important final steps toward the development of a safer, synthetic alternative to current heparin. The researchers believe that kilogram quantities of the new drug could be developed in under five years.
The idea of taking a mature cell and removing its identity (nuclear reprogramming) so that it can then become any kind of cell, holds great promise for repairing damaged tissue or replacing bone marrow after chemotherapy.
› Verified 5 days ago
| Entity Name | Metro Infectious Disease Consultants Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235125717 PECOS PAC ID: 3072425784 Enrollment ID: O20031103000274 |
News Archive
Investigators at Montefiore Health System and Albert Einstein College of Medicine of Yeshiva University will present multiple findings at the Alzheimer's Association International Conference, taking place July 18-23 in Washington, D.C. Research topics include risk factors for developing amnestic mild cognitive impairment (aMCI)—a condition characterized by memory problems, and is most often a precursor of Alzheimer's dementia.
Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, today announced that 12-month data from its Phase 2 CUPID clinical trial of MYDICAR demonstrated significant improvements in clinical outcomes and key disease markers in advanced heart failure patients treated with the genetically-targeted enzyme replacement therapy.
Even though there is considerable opinion among Israelis that much of the public social programs and projects should be the responsibility of the government, the public nevertheless views philanthropic activity in a highly positive light and believes that it plays an essential role in Israeli society.
With a $4.6 million grant from the National Institutes of Health (under the Bioengineering Research Partnership program), research led by Rensselaer Polytechnic Institute will make its important final steps toward the development of a safer, synthetic alternative to current heparin. The researchers believe that kilogram quantities of the new drug could be developed in under five years.
The idea of taking a mature cell and removing its identity (nuclear reprogramming) so that it can then become any kind of cell, holds great promise for repairing damaged tissue or replacing bone marrow after chemotherapy.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ram L Ramani, MD 901 Mcclintock Dr, Suite 202, Burr Ridge, IL 60527-0872 Ph: (888) 220-6432 | Dr Ram L Ramani, MD 901 Mcclintock Dr, Suite 201, Burr Ridge, IL 60527-0872 Ph: (888) 220-6432 |
News Archive
Investigators at Montefiore Health System and Albert Einstein College of Medicine of Yeshiva University will present multiple findings at the Alzheimer's Association International Conference, taking place July 18-23 in Washington, D.C. Research topics include risk factors for developing amnestic mild cognitive impairment (aMCI)—a condition characterized by memory problems, and is most often a precursor of Alzheimer's dementia.
Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, today announced that 12-month data from its Phase 2 CUPID clinical trial of MYDICAR demonstrated significant improvements in clinical outcomes and key disease markers in advanced heart failure patients treated with the genetically-targeted enzyme replacement therapy.
Even though there is considerable opinion among Israelis that much of the public social programs and projects should be the responsibility of the government, the public nevertheless views philanthropic activity in a highly positive light and believes that it plays an essential role in Israeli society.
With a $4.6 million grant from the National Institutes of Health (under the Bioengineering Research Partnership program), research led by Rensselaer Polytechnic Institute will make its important final steps toward the development of a safer, synthetic alternative to current heparin. The researchers believe that kilogram quantities of the new drug could be developed in under five years.
The idea of taking a mature cell and removing its identity (nuclear reprogramming) so that it can then become any kind of cell, holds great promise for repairing damaged tissue or replacing bone marrow after chemotherapy.
› Verified 5 days ago
Chad T Whelan, MD Infectious Disease Medicare: Medicare Enrolled Practice Location: 180 Harvester Dr Ste 110, Burr Ridge, IL 60527 Phone: 773-834-4064 | |
Dr. Vyjayanthi Atluri, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 6101 S County Line Rd, Burr Ridge, IL 60527 Phone: 630-686-9000 | |
Alan R Leff, MD Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 180 Harvester Dr Ste 110, Burr Ridge, IL 60527 Phone: 773-834-4064 | |
Jayant Malhotra, M.D. Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 25 Rodeo Dr, Burr Ridge, IL 60527 Phone: 630-789-6618 | |
Edgar Davila, Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 124 79th St, Burr Ridge, IL 60527 Phone: 773-641-2037 | |
William Stoecker, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 901 Mcclintock Dr Ste 202, Burr Ridge, IL 60527 Phone: 888-220-6432 | |
Sarah H Glavin, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 180 Harvester Dr Ste 110, Burr Ridge, IL 60527 Phone: 773-834-4064 |